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Honey has been considered as a remedy in wound healing since ancient times. However, as yet, there are inadequate supportive
robust randomized trials and experimental data to fully accept honey as an eﬀective medical product in wound care. Manuka
honey has been claimed to have therapeutic advantages over other honeys. Recently, it has been documented that the pronounced
antibacterialactivityofmanukahoneyisdue,atleastinpart,toreactivemethylglyoxal(MG).TheconcentrationofMGinmanuka
honeys is up to 100-fold higher than in conventional honeys. MG is a potent protein-glycating agent and an important precursor
of advanced glycation end products (AGEs). MG and AGEs play a role in the pathogenesis of impaired diabetic wound healing and
canmodifythestructureandfunctionoftargetmolecules.ThiscommentarydescribestheconcernthatMGinmanukahoneymay
delay wound healing in diabetic patients. Further detailed research is needed to fully elucidate the participation of honey/derived
MG in healing diabetic ulcers. We advocate randomized controlled trials to determine eﬃcacy and safety of manuka honey in this
population.
1.Introduction
The prevalence of diabetes is rapidly increasing worldwide.
The occurrence of diabetic foot ulcers is a serious complica-
tion which negatively aﬀects patients’ quality of life. Among
persons diagnosed with diabetes mellitus, the prevalence
of foot ulcers is 4%–10% [1]. Treatment of foot ulcers is
protracted and intensive and associated with high costs.
Various approaches have been developed for the treatment
of diabetic ulcers including topical wound-care therapies.
Current therapeutic products which are being used
widely in wound care, such as silver sulfadiazine, hydrogel,
hydrocolloid and alginate dressings impregnated with silver,
are generally accepted as being useful for control of bacterial
infections. Increased use of ionic silver in wound care
has created some concern regarding the development of
bacterial resistance [2, 3]. Silver resistance has already
been documented in bacterial isolates including Escherichia
coli [4], Enterobacter cloacae [4], Klebsiella pneumonie [4],
Salmonella typhimurium [5]a n dAcinetobacter baumani [6].
With increasing frequency, modern medicine directs
attention to natural products with antimicrobial activity
and their use in clinical practice. The major arguments for
implementing natural products such as honey, aloe vera or
curcumin are the low cost and absence of antimicrobial
resistance risk in comparison with conventional wound-
care products. Moreover, some of the natural therapies such
as maggot debridement therapy and phage therapy have
recentlybeenreexaminedfortheirpotentialusefulnessinthe
treatment of wounds that are diﬃcult to heal [7–10].
2.Honey asa TraditionalAntimicrobialAgent
Historically, honey has been used in the treatment of a
broad spectrum of wounds. It is well documented that
honey can act as an antimicrobial and antioxidative agent
as well as an immunomodulator with both pro- and anti-
inﬂammatory eﬀects [11–15] (Figure 1). Recent research has
concentrated on the antimicrobial activity of diﬀerent types
of honey rather than its eﬀect on wound healing [16–20].
Honey derived from the ﬂoral source of Leptospermum spp.
(manuka) has been claimed to have therapeutic advantages
over other honeys [21–23]. Manuka honeys exhibit notable
antimicrobial activity which cannot be attributed to the
peroxide present [24, 25]. It has been documented that2 Evidence-Based Complementary and Alternative Medicine
Antimicrobial activity
-H y d r o g e np e r o x i d e
- Phytochemical factors
- 5.8 kDa component
- Phenolic compounds
AGEs
Diabetes complications
MG
Manuka honey
Immunomodulatory
activity
- Acidic pH (range, 3.2–4.5)
- High osmolarity
Antioxidative
activity
- Honeybee derived MRJP1
Figure 1: Main properties of manuka honey in the treatment
of diabetic ulcers. The black arrow represents known action, the
white arrows represent hypothetical mechanisms of action. MG:
methylglyoxal; AGEs: advanced glycation end products; MRJP1:
major royal jelly protein 1.
the pronounced antibacterial activity of manuka honey
directly originates from the methylglyoxal (MG) it contains
[26, 27]. Honey derived from this speciﬁc plant in New
Zealand and Australia gave rise to Medihoney—widely used
medical honey. George and Cutting [28] compared the
sensitivity of 130 clinical isolates to this medical honey. They
demonstrated that manuka honey is eﬀective against a broad
range of microorganisms including multi-resistant strains
[28]. In a very recent study it has been reported that manuka
honey has antimicrobial activity against clinical isolates of
Campylobacter spp. [29]. Along with MG, the hydrogen
peroxide, ﬂavonoids as well as aromatic acids present in
natural honeys also act as antimicrobial substances.
3. ClinicalEvidence for the Use of Honey in
the Management of ChronicWounds
The ﬁndings of animal studies and of several randomized
clinical trials involving more than 2000 participants have
provided compelling evidence that honey can accelerate
wound healing [22]. On the other hand, the quality of
reported trials is variable and evidence to date supports
honey only as a treatment of mild-to-moderate superﬁcial
and partial thickness burns [30]. Authors of a recent system-
atic review assert that there is insuﬃcient evidence to guide
clinical practice for other wound types [30]. Jull and co-
workers established that honey-impregnated dressings did
not signiﬁcantly improve venous ulcer healing at 12 weeks
comparedwithusualcare[31].Moreover,thesedressingsdid
not signiﬁcantly improve time to healing, change in ulcer
area, incidence of infection or quality of life. On the other
hand,twoveryrecentclinicaltrialssuggestthathealingtimes
and incidence of infection after treatment with honey are
reducedcomparedtoconventionaltreatment,andtheresults
are of clinical signiﬁcance [32, 33]. The main limitation
of above two trials is that patient numbers recruited for
inclusion were insuﬃcient to reach statistical signiﬁcance.
Manuka honey is the type of honey most often studied in
randomized controlled studies. Six trials (n = 701) [31–36]
recruited participants with chronic wounds, three of which
recruited participants with leg ulcers [31–33]. In all three
trials manuka honey dressing was used. The participants
with history of diabetes were excluded from two trials [31,
33]. Although, diabetic participants with venous ulcers were
notexcludedintheremainingtrial[32],theeﬀectofmanuka
honeyinthetreatmentofulcersinpatientswithdiabetes was
not speciﬁcally examined.
Non-manuka honey was recently compared to povidone
iodine in the treatment of Wagner type II diabetic foot
ulcers [37]. Ulcer healing was not signiﬁcantly diﬀerent in
both groups and the authors deduced that honey dressing
representsasafealternativedressingfortreatmentofdiabetic
foot ulcers. In addition, Eddy and Gideonsen [38]r e p o rt e da
case where ordinary honey was applied to patient’s heel and
forefoot diabetic ulcers in order to avoid the leg amputation.
Granulation tissue appeared within 2 weeks and the ulcers
healed in 6–12 months.
The eﬀect of diﬀerent honey on healing has not been
compared invivoineithertheanimalorthehumanmodel.It
wouldbeinteresting tocompareeﬀectivenessofseveraltypes
of honey in randomized controlled clinical trials recruiting
participants with diabetic ulcers. It has been described that
the Slovak forest honey has comparable antibacterial activity
to manuka honey against nosocomial and skin pathogens in
vitro [20].
4.MethylglyoxalConcentrations inHoney
MG and other dicarbonyls have been identiﬁed in a range
of foods and beverages, including wine [39], beer [39],
bread [40], soya [41] and honey [42]. MG in manuka
honeys is derived from the non-enzymatic conversion of
dihydroxyacetone which occurs at high levels in the nectar
[42]. Freshly produced manuka honey contained low levels
of MG (139–491mgkg−1) but during storage at 37◦Ci t s
content increased. The levels of MG in multi-ﬂoral honeys
are low, ranging from 0.4 to 5.4mgkg−1 [43]. In two
studies, high levels of MG were reported in manuka honeys
ranging from 48 to 743mgkg−1 [27] and 189 to 835mgkg−1
[44], respectively. It has been suggested that concentrations
of MG above 150mgkg−1 are directly responsible for the
characteristic antibacterial properties of manuka honey [44].
5. Biological Propertiesof MG andAGEs
The 1,2-dicarbonyl compounds, including MG, glyoxal and
3-deoxyglucosone, are generated either endogenously by cell
metabolism, glucose oxidation and lipid peroxidation or by
degradation of carbohydrates in foods and beverages. Highly
reactive dicarbonyls attack the lysine, arginine (Arg) and
cysteine residues of long-lived proteins, such as collagens,
to form irreversible AGEs causing changes in collagen
pathophysiology that result in disruption of normal collagen
matrix remodeling [45].Evidence-Based Complementary and Alternative Medicine 3
AGEs are complex, heterogenous molecules that cause
protein cross-linking, exhibit browning and generate ﬂuo-
rescence [46]. Not all AGEs have been identiﬁed and the
mechanisms underlying their formation remain unclear.
AGEs exert their actions either directly or through a receptor
system that includes two types of cell-surface AGE receptors
[47, 48]. It has been found that a large portion of AGEs
and their precursors in the body are derived from exogenous
sources [49, 50].
MG-induced modiﬁcations of Arg residues in collagen
could be a key factor in the impaired degradation of
collagen that promotes ﬁbrosis in chronic tissue infections
[51]. Interestingly, MG increased the apparent molecular
weight of collagen, which is suggestive of increased collagen
cross-linking [45]. MG also changes the structure and
function of many important immunological proteins and
enzymes, and reduces the eﬃciency of peripheral blood
immune-cell response [52]. The administration of MG to
rats induced severe negative changes in cutaneous vessels,
suggesting decreased peripheral perfusion by an impaired
microcirculation [53]. Furthermore, authors observed that
ulcers in MG-treated rats failed to provide actively migrating
cells from peripheral regions.
Treatment of early-passage human skin ﬁbroblasts with
400μM of MG results in accelerated aging and the appear-
ance of the senescent phenotype [54].
6. The Roles of MG and AGEs in Impairment of
DiabeticWoundHealing
The scope of MG damage in diabetes is huge, because
MG is able to form adducts on protein, lipoproteins and
DNAs at any site where its concentration is high. It has
also been suggested that MG glycation could be a link
between diabetes and infection susceptibility [52]. MG-
induced immune damage might provide a link between
hyperglycemia and diabetes-related infection risk [52].
Data from recent experimental studies indicate that not
only MG but also AGEs may play a role in the pathogenesis
of impaired diabetic wound healing and might have sep-
arate consequences for immunity [54–58]. Increased AGE
accumulation, along with expression of their receptors, are
associated with formation of diabetic atheromatous lesions,
triggering their destabilization, impairing ischemia-induced
neovascularization and formation of collateral circulation,
expanding vessel extracellular matrix, and disrupting the
expressionofendothelialnitrousoxidesynthetase[47,48,58,
59].
The accumulation of AGEs in the extracellular matrix
causes aberrant cross-linking, resulting in decreased vessel
elasticity. It has also been shown that keratinocyte migration
is inhibited by AGEs accumulation under high-glucose
conditions [60]. In diabetes, AGEs can enhance the activity
of neutrophils, with change in cellular biological behaviors
which might be one of the main reasons responsible for
chronic inﬂammation [61]. The sustained inﬂammatory
response occurs following interaction of AGEs with their
receptors and release of pro-inﬂammatory mediators such as
tumornecrosisfactorαandproductionofdestructivematrix
metalloproteinases which limit wound closure [56]. In
addition, Goova et al. [56] have demonstrated that blocking
receptors for AGEs restores impaired wound healing in
diabetic mice.
7. Conclusion
A number of randomized clinical trials suggest that medical
grade honey promotes wound healing but most of them have
not included diabetic patients with chronic leg ulcers and
nearlythree-quartersofclinicaltrialshavefocusedontheuse
of honey for acute wounds, in particular burns. In general,
repair of tissue damage in diabetic foot disease is accom-
panied with several pathophysiological mechanisms. Since
manuka honey contains high levels of MG, we speculate that
patients with diabetes may be at risk due to either the direct
negative eﬀect of MG on cells and components in the wound
or the indirect formation of AGEs, which could impair the
wound-healing process.
We believe that honey is an eﬀective alternative dressing
for treatment of many types of chronic wounds. However,
MG may have a detrimental eﬀect on diabetic ulcers. Further
research is needed to fully elucidate the eﬀect of honey-
derived MG in the treatment of diabetic ulcers. In addition,
honeys with varying levels of MG should be subjected
to randomized comparative clinical trials in treatment of
diabetic ulcers.
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